Journal of Hepatology
Volume 52, Issue 4 , Pages 540-549 , April 2010

Impaired liver regeneration of steatotic rats after portal vein ligation: A particular emphasis on 99mTc-DISIDA scintigraphy and adiponectin signaling

  • Ing-Tsung Hsiao

      Affiliations

    • Department of Medical Imaging and Radiological Sciences, Chang Gung University, Taoyuan, Taiwan
    • Both contributed equally.
    • ,
  • Kun-Ju Lin

      Affiliations

    • Departments of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan
    • Both contributed equally.
    • ,
  • Shi-Ing Chang

      Affiliations

    • Department of Medical Imaging and Radiological Sciences, Chang Gung University, Taoyuan, Taiwan
    • ,
  • Tzu-Chen Yen

      Affiliations

    • Departments of Nuclear Medicine and Molecular Imaging Center, Chang Gung Memorial Hospital, Taoyuan, Taiwan
    • ,
  • Tse-Ching Chen

      Affiliations

    • Department of Pathology, Chang Gung Memorial Hospital, Taoyuan, Taiwan
    • ,
  • Ta-Sen Yeh

      Affiliations

    • Department of Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan
    • Corresponding Author InformationCorresponding author. Address: Department of Surgery, Chang Gung Memorial Hospital, 5 Fu-Hsing Street, Kwei-Shan Shiang, Taoyuan 886-3, Taiwan. Tel.: +886 3281200x3219; fax: +886 3 3285818.

Received 22 April 2009 ,Revised 2 September 2009 ,Accepted 3 September 2009.

References 

  1. De Baere T, Roche A, Elias D, et al. Preoperative portal vein embolization for extension of hepatectomy indications. Hepatology. 1996;24:1386–1391
  2. Nagino M, Kamiya J, Nishio H, et al. Two hundred forty consecutive portal vein embolizations before extended hepatectomy for biliary cancer. Surgical outcome and long-term follow-up. Ann Surg. 2006;243:364–372
  3. Azoulay DA, Castaing D, Krissat J, et al. Percutaneous portal vein embolization increases the feasibility and safety of major liver resection for hepatocellular carcinoma in injuried liver. Ann Surg. 2000;232:665–672
  4. Wakabayashi H, Ishimura K, Okano K, et al. Application of preoperative portal vein embolization before major hepatic resection in patients with normal or abnormal liver parenchyma. Surgery. 2002;131:26–33
  5. Denys AL, Abehsera M, Sauvanet A, et al. Failure of right portal vein ligation to induce left lobe hypertrophy due to intrahepatic portoportal collaterals: successful treatment with portal vein embolization. Am J Roentgenol. 1999;173:633–635
  6. Broering DC, Hillert C, Krupski G, et al. Portal vein embolization vs portal vein ligation for inducing hypertrophy of the future liver remnant. J Gastrointest Surg. 2002;6:905–913
  7. Capussotti L, Muratore A, Baracchi F, et al. Portal vein ligation as an efficient method of increasing the future liver remnant volume in the surgical treatment of colorectal metastases. Arch Surg. 2008;143:978–982
  8. Angulo P. Nonalcoholic fatty liver disease. N Engl J Med. 2002;346:1221–1231
  9. Karoui M, Penna C, Amin-Hashem M, et al. Influence of preoperative chemotherapy on risk of major hepatectomy for colorectal liver metastases. Ann Surg. 2006;243:1–7
  10. Masi G, Loupakis F, Pollina L, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-flurouracil/leukoverin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249:420–425
  11. Vauthey JN, Pawlik TM, Ribero D, et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90-day mortality after surgery for hepatic colorectal metastases. J Clin Oncol. 2006;24:2065–2072
  12. Nakano H, Oussoultzoglou E, Rosso E, et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann Surg. 2008;247:118–124
  13. Vetelainen R, van Vliet A, van Gulik TM. Severe steatosis increases hepatocellular injury and impairs liver regeneration in a rat model of partial hepatectomy. Ann Surg. 2007;245:44–50
  14. Lin KJ, Liao CH, Hsiao IT, et al. Improved hepatocyte function of future liver remnant of cirrhotic rats after portal vein ligation: a bonus other than volume shifting. Surgery. 2009;145:202–211
  15. Brunt EM, Janney CJ, Di Bis ceglie AM, et al. Non-alcoholic steatohepatitis: a proposal for grading and staging the histologic lesions. Am J Gastroenterol. 1999;94:2467–2474
  16. Neuschwander-Tetri BA, Caldwell SH. Non-alcoholic steatohepatitis: summary of an AASLD single topic conference. Hepatology. 2003;37:1202–1219
  17. Brown PH, Juni JE, Lieberman DA, et al. Hepatocyte versus biliary disease: a distinction by deconvolutional analysis of Tc-99m-IDA time–activity curves. J Nucl Med. 1988;29:623–630
  18. Jagge EP, Campbell DA, Reichle R, et al. Quantitative scintigraphy with deconvolutional analysis for the dynamic measurement of hepatic function. J Surg Res. 1987;46:605–612
  19. Brown PH, Krishnamurthy GT, Bobba VR, et al. Radiation dose calculation for Tc-99m HIDA in health and disease. J Nucl Med. 1981;22:177–181
  20. Kubota K, Makuuchi M, Kusaka K, et al. Measurement of liver volume and hepatic functional reserve as a guide to decision-making in resectional surgery for hepatic tumors. Hepatology. 1997;26:1176–1181
  21. Michalpoulos GK, DeFrances M. Liver regeneration. Science. 1997;276:60–66
  22. Mayeux PR. Pathobiology of lipopolysaccharide. J Toxicol Environ Health. 1997;51:415–435
  23. Hoefs JC, Chen PT, Lizotte P. Noninvasive evaluation of liver disease severity. Clin Liver Dis. 2006;10:535–562
  24. Krishnamurthy GT, Krishnamurthy S. Nuclear hepatology: a textbook hepatobiliary disease. New York: Springer; 2000;
  25. Boyer JL. Nuclear receptor ligands: rational and effective therapy for cholestatic liver disease. Gastroenterology. 2005;129:735–740
  26. Pizarro M, Balasubramaniyan N, Solis N, et al. Bile secretory function in obese Zucker rat: evidence of cholestasis and altered bile canalicular transport function. Gut. 2004;53:1837–1843
  27. Daniel GB, DeNovo RC, Schultze AE, et al. Hepatic extraction efficiency of technetium-99m- mebrofenin in the dog with toxic-induced acute liver disease. J Nucl Med. 1998;39:1286–1292
  28. Chavez-Cartaya R, Ramirez P, Fuente T, et al. Blood clearance of 99mTc-trimethyl-Br-IDA discriminates between different degrees of severe liver ischemia–reperfusion injury in the rat. Eur Surg Res. 1997;29:346–355
  29. Joseph B, Bhargava KK, Tronco G, et al. Regulation of hepatobiliary transport activity and non-invasive identification of cytokine-dependent liver inflammation. J Nucl Med. 2005;46:146–152
  30. Yamauchi T, Kamon J, Ito Y, et al. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature. 2003;423:762–769
  31. Yamauchi T, Kamon J, Ito Y, et al. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med. 2002;8:1288–1295
  32. Yamauchi T, Nil Y, Maki T, et al. Targeted disruption of AdipoR1 and AdipoR2 causes abrogation of adiponectin binding and metabolic actions. Nat Med. 2007;13:332–339
  33. Shklyaev S, Aslanidi G, Tennant M, et al. Sustained expression of transgene adiponectin offsets the development of diet-induced obesity in rats. Proc Natl Acad Sci USA. 2003;100:14217–14222
  34. Berg AH, Combs TP, Du X, et al. The adipocyte-secreted protein Acrp30 enhances hepatic insulin action. Nat Med. 2001;7:947–953
  35. Fruebis J, Tsao TS, Javorschi S, et al. Proteolytic cleavage product of 30kDa adipocyte complement-related protein increases fatty acid oxidation in muscle and causes weight loss in mice. Proc Natl Acad Sci USA. 2001;98:2005–2010
  36. Masaki T, Chiba S, Tatsukawa H, et al. Adiponectin protects LPS-induced liver injury through modulation of TNF-alpha in KK-Ay obese mice. Hepatology. 2004;40:177–184
  37. Xu A, Wang Y, Keshaw H, et al. The fat-derived hormone adiponectin alleviates alcoholic and non-alcoholic fatty liver disease in mice. J Clin Invest. 2003;112:91–100
  38. Larter C, Yeh MM, Williams J, et al. MCD-induced steatohepatitis is associated with hepatic adiponectin resistance and adipogenic transformation of hepatocytes. J Hepatol. 2008;49:407–416
  39. Tsuchida A, Yamauchi T, Ito T, et al. Insulin/Foxol pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem. 2004;279:30817–30822
  40. Kadowaki T, Yamauchi T. Adiponectin and adiponectin receptors. Endocr Rev. 2005;26:439–451
  41. Hsu MH, Savas U, Griffin KJ, et al. Identification of peroxisome proliferator-activated receptor alpha in HepG2 cells. J Biol Chem. 2001;276:27950–27958
  42. Yang Q, Ito S, Gonalez FJ. Hepatocyte-restricted constitutive activation of PPAR alpha induces hepatoproliferation but not hepatocarcinogenesis. Carcinogenesis. 2007;28:1171–1177

PII: S0168-8278(10)00013-9

doi: 10.1016/j.jhep.2010.01.005

Journal of Hepatology
Volume 52, Issue 4 , Pages 540-549 , April 2010

Article Tools

* Image Usage & Resolution